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Heart functionAbstract Aims: The aim was to evaluate the cardio-protective effect of atorvastatin in combina-
tion with standard chronic heart failure (CHF) therapy that might improve cardiac function,
remodeling, and further delay the progression of CHF in patients and rats.
Methods and results: CHF patients (n= 20 per group) with left ventricular ejection fraction (LV-
EF) <45% were randomized into: standard anti-failure treatment alone (controls) and standard
anti-failure treatment plus atorvastatin (40 mg/day) for 6 weeks. After 6 weeks, the patients were
assessed using echocardiography. Laboratory evaluation for lipid proﬁles, high sensitive C-reactive
protein (hs-CRP), cardiac troponin-T (cTnT) and malondialdehyde (MDA) were performed in all
patients. In parallel, rats (n= 10 per group) received treatment for 4 weeks and were divided as
follows: saline treated (control, 1 ml intraperitoneal, IP), doxorubicin treated (2.5 mg/kg, IP), ator-
vastatin–doxorubicin treated (10 mg/kg, orally), and digoxin–doxorubicin treated (0.02 mg/kg,
orally). The same laboratory analysis including histopathology of heart tissues was performed on
the rats.
In patients, atorvastatin improved heart function (increased LV-EF%, LV-fraction shorting (LV-
FS%), and E/A velocity ratio; decreased LV-end diastolic diameter (LV-EDD) and LV-end systolic
diameter (LV-ESD)) and signiﬁcantly reduced serum lipid proﬁles, cTnT, hs-CRP and MDA versus
patient controls. In rats, atorvastatin improved signs of CHF, systolic blood pressure, reduced
290 I. Elmadbouh et al.serum lipid proﬁles, cTnT, hs-CRP and tissue MDA; less cardiac necrosis and ﬁbrosis with
enhancement of neo-vascularization versus other doxorubicin-treated rats.
Conclusions: Atorvastatin with standard CHF therapy improved cardiac function and remodeling.
Cardio-protective ‘‘pleiotropic’’ actions of atorvastatin are anti-inﬂammatory, anti-ﬁbrotic and
anti-oxidative. Thus, atorvastatin has a potential therapeutic value in the management of CHF
patients.
ª 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of
Cardiology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).1. Introduction
Although 3-hydroxy-3-methylglutaryl (HMG) coenzyme-A
reductase inhibitors (statins) prevent important causative fac-
tors for chronic heart failure (CHF), myocardial damage and
ischemia, the beneﬁts of statins and lowering low-density
lipoprotein (LDL-c) in CHF patients have been questioned.1
Statins, in addition to standard medications for heart failure,
are associated with an improvement in morbidity and mortal-
ity and signiﬁcantly reduced subsequent hospitalizations
among patients taking them as compared to the placebo
group.2,3 Statin therapy was associated with improved survival
in both; patients with ischemic heart failure and patients with
non-ischemic heart failure.4 A previous meta-analysis2,3,5 of 10
randomized placebo-controlled trials (6 for atorvastatin, 3 for
rosuvastatin, and 1 for simvastatin) suggest that statins may be
safe and improve left ventricular (LV) ejection fraction (LV-
EF), decrease brain natriuretic peptide (BNP) levels and
decrease hospitalizations for worsening CHF.4,6
Despite recent therapeutic advances, the appropriate role of
drug-speciﬁc statin therapy in the CHF population, however,
remains unclear.2 There exists an increasing need to ﬁnd new
therapeutic strategies to reduce high mortality and morbidity
in this population. Statins, a class of agents for lowering blood
lipids, have been shown to reduce adverse cardiovascular
events in atherosclerosis related diseases in patients with docu-
mented coronary artery disease (CAD).7 Consequently, the
current guidelines for the management of CHF target the cau-
sal pathological disease, control of heart rate, and reduction of
ﬂuid retention. Thus, combined therapy with angiotensin-
converting enzyme (ACE) inhibitors or angiotensin II receptor
blockers, b-adrenergic or aldosterone blockers, and diuretics
seems to be the current (standard) optimal therapeutic strat-
egy.4,7 Most of these effects can target important components
of the complex physiopathology of heart failure.8 Thus, con-
cern has been raised about the potential beneﬁts of statins in
patients with CHF of multiple etiologies.4,6
Several studies in rat models and patients have suggested
that statins may directly improve LV relaxation and function
by reducing LV hypertrophy and ﬁbrosis, and increasing arte-
rial compliance.9,10 Some of the effects of statins improve
endothelial function.11,12 However, the best-characterized
pleiotropic effects of statins are their anti-inﬂammatory13
and antioxidant actions14,15 and their protective effect against
endothelial and LV dysfunction.12,16 We chose a rat model
with doxorubicin induced heart failure because of the com-
monly known cumulative cardiotoxic effect in cancer
patients.17–20 To date, no such studies have been performedon the cardio-protective potential of atorvastatin in doxorubi-
cin-induced cardiomyopathy.
In this study, we investigated whether the early use of
atorvastatin in combination with standard CHF therapy might
improve cardiac function and remodeling in CHF patients and
also further delay the progression of CHF in doxorubicin-
induced heart failure in rat models.
2. Methods
2.1. Clinical study
2.1.1. Subjects
The present study included 40 patients recruited from the
Cardiology Department outpatient clinic at Menouﬁya
University Hospital between January 2010 and March 2012.
Eligible patients were men and women of 35–75 years of age
with a clinical diagnosis of CHF. Written informed consent
was obtained from each participant before inclusion in the
study. Ethical approval for this investigation was obtained
from the Research Ethics Committee, Faculty of Medicine,
Menouﬁya University.
CHF diagnosis was determined by echocardiography eval-
uation. These patients were chosen according to the following
inclusion and exclusion criteria: Inclusion Criteria: (1) patients
who had symptoms according to New York Heart Association
(NYHA) functional class II or III, assessed by a detailed his-
tory and clinical examination; (2) patients with non-ischemic
heart failure with no history of myocardial infarction and
cardiac catheterization without signiﬁcant CAD; (3) patients
with ﬁndings of a dilated LV end diastolic diameter (LV-
EDD) (>60 mm), affected LV fraction shortening (LV-FS)
(<25%) and LV-EF (<45%); and (4) patients who used stan-
dard anti-heart failure drugs in the form of loop diuretics and
spironolactone, b-blockers, ACE inhibitors or angiotensin II
receptor blockers with or without digoxin, regularly, for at
least 1 month prior to the study. Exclusion criteria: (1) patients
with CHF caused by ischemic heart diseases; (2) valvular heart
diseases; (3) rhythmic dysfunction; (4) renal, hepatic, or pul-
monary dysfunction; (5) patients with uncontrolled diabetes;
and (6) patients with uncontrolled hypertension (HTN).
All patients with non-ischemic CHF were randomized and
divided into two groups (20 patients in each group): (a)
Control group: received standard anti-failure treatment in
unchanged dose for at least one month before the study and
for 6 weeks during the study without any statin therapy. (b)
Statin-treated group: received standard anti-failure treatment
in unchanged dose for at least one month before the study
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tablets, Pﬁzer, Egypt), of 40 mg/day for 6 weeks. The dose of
40 mg per day atorvastatin was chosen because this dose was
within the dose range observed in the clinical setting, based
on previous studies.21–24
2.1.2. Echocardiography in patients
Baseline echocardiography was performed on all patients with
CHF at the beginning of study and again after 6 weeks of
treatment. Two-dimensional and Doppler echocardiography
(Vivid 7, Milwaukee, USA) were performed in the left lateral
decubitus position with a broadband (1.5–4 MHz) phased
array transducer at rest. Echo evaluations included: LV-
EDD, end systolic diameter (LV-ESD), LV-FS and LV-EF.
Doppler ﬂow velocities (E and A waves) were taken at the level
of the mitral valve in the apical four-chamber view in diastole
with the Doppler probe placed at the edge of the mitral leaﬂets.
The peak of early (E) and late ﬁlling waves (A) was measured
(E/A ratio). Echocardiograms were read centrally in a blinded
manner.
2.1.3. Laboratory analysis in patients
Baseline venous blood samples were collected from all patients
at the beginning of the study and after 6 weeks of treatment.
The serum was separated by centrifugation and frozen at
80 C until analysis. Biochemical parameters in serum were
evaluated using commercially available kits such as total cho-
lesterol, triglycerides, high density lipoprotein-cholesterol
(HDL-c) (Stanbio Laboratory, USA) and low density lipopro-
tein-cholesterol (LDL-c) (Quimica Clinica, Aplicada, Spain).
Serum cardiac troponin T (cTnT, Boehringer, Germany) and
high sensitive C-reactive proteins (hs-CRP, Monobind, USA)
were measured by using enzyme-linked immunosorbent assay
(ELISA). Serum malondialdehyde (MDA) activity was
measured by the NWLSS NWDA01 assay (Northwest Life
Science Specialties, LLC). This assay is based on the reaction
of MDA with thiobarbituric acid (TBA) using
spectrophotometry.
2.2. Pre-clinical study
2.2.1. Animals
Forty male albino rats (total body weight, 150–200 g) were
acclimated for one week prior to the experiment. Rats were
housed in plastic cages, had free access to water and were given
a semi-synthetic balanced diet with controlled temperature
(21–23 C) and lighting (12 h light/dark cycles). This study
was approved by the Animal Experimentation Ethics Commit-
tee of the Egyptian National University.
Rats were divided into 4 groups with 10 rats per group: (a)
Control group: Rats received 1 ml of normal saline (El-Nasr
Company, Egypt) intra-peritoneally (IP) for 4 weeks. (b)
Doxorubicin group: Rats were injected IP with doxorubicin
(doxorubicin hydrochloride, Adriblastina vials 10 mg pow-
der dissolved in normal saline, Farmitalia, Italy) doses of
2.5 mg/kg (body weight) every other day over a period of
two weeks (i.e. six equal injections) for a cumulative dose
of 15 mg/kg and then they were given 1 ml saline IP for
2 weeks as previously described.20 (c) Atorvastatin–doxorubi-
cin group: Rats were treated with atorvastatin (Lipitor
tablets 10 mg dissolved in normal saline, Pﬁzer, Egypt) dosesof 10 mg/kg/day given by oral gavage for 4 weeks and on the
15th day were injected with 2.5 mg/kg of doxorubicin IP every
other day for 2 weeks. The dose of 10 mg/kg per day atorva-
statin was chosen because the plasma concentration achieved
in rats with this dose was within the dose range observed in
the clinical setting.25–27 (d) Digoxin–doxorubicin group: Rats
were treated with digoxin (Lanoxin tablets 0.25 mg dissolved
in normal saline, GlaxoSmithKline, Egypt) by oral gavage for
4 weeks with doses of 0.02 mg/kg/day28, and on the 15th day
were injected with 2.5 mg/kg doxorubicin IP every other day
for 2 weeks.2.2.2. Systolic blood pressure measurement in rats
Non-invasive systolic blood pressure (SBP) was measured in
conscious animals with a tail cuff sphygmomanometer
(Harvard, UK). For each animal, the SBP was calculated as
the average of three independent measurements at each
session, as described previously.9,27
2.2.3. Laboratory assays in rats
After 4 weeks of treatment, the blood was collected from the
retro-orbital plexus of overnight fasted rats using micro-capil-
lary tubes. The serum was separated using a sterile pipette after
centrifugation at 3000 rpm for 15 min. Similarly serum lipid
proﬁles (total cholesterol, triglyceride, LDL-c and HDL-c),
hs-CRP, cTnT and MDA activity the patients were analyzed.
The rats were then euthanized by an overdose of anesthetic
ether vapors. Total body weight was obtained prior to surgical
removal of the heart. Heart weights were measured and cut
into two parts: one for histopathology and the other for
homogenization with MDA assay (see below).
Myocardial lipid peroxidation was assessed by determin-
ing TBA reactive substances using a modiﬁed TBA method.20
Brieﬂy, the heart tissue from treated rat groups were washed
in ice-cold 0.9% saline and homogenized using a tissue
homogenizer to get 10% homogenate and buffered in 0.9%
KCl (pH 7.4). The homogenate was centrifuged for 10 min
and the supernatant was used for measurement of MDA
activity and protein levels using the Lowry protein assay.
Cardiac tissue of MDA was measured by spectrophotometry
(see above).
2.2.4. Rat heart histopathology
The heart was excised and ﬁxed in neutral buffered formalin.
The tissues were embedded in parafﬁn and sectioned at 5 lm
for staining. Heart sections were stained with Hematoxylin
and Eosin (H&E) for evaluation of histology. Weigert’s Resor-
cin-Fuchsin stain was used for elastic ﬁber staining in the
blood vessels. Masson’s trichrome was used as ﬁbrosis assay
for distinguishing muscle from interstitial connective tissue.
Images were analyzed under optical microscopy at magniﬁca-
tions of 400–1000·.
2.3. Statistical analysis
Variables are presented as numbers, percentages (%), or
mean±standard error (SE) as indicated. Student’s t-test,
Chi-Square (v2) test, or Fisher’s exact test and a one way
ANOVA test and an un-paired t-test were used to compare
mean values between the treatment groups and the controls,
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sided P value. The adjusted P value of <0.05 was considered
as being statistically signiﬁcant. Results were analyzed by the
statistical software package SPSS version 11 for window (SPSS
Inc., Chicago, IL, USA).
3. Results
3.1. Results of clinical study
In non-ischemic CHF patients, there was no signiﬁcant
difference between patient groups regarding age, sex, HTN,
smoking, diabetes and standard anti-heart failure therapy
(P> 0.05) (Table 1).
After 6 weeks of treatment, atorvastatin-treated patients
showed a signiﬁcant decrease in both LV-EDD and LV-
ESD, but showed a signiﬁcant increase in LV-EF%, LV-
FS% and E/A velocity ratio compared to those of control
patients (P< 0.05) (Fig. 1).
Atorvastatin-treated patients showed a signiﬁcant decrease
in serum of total cholesterol, triglyceride and LDL-c
(P< 0.05), hs-CRP, cTnT and MDA (P< 0.01), and no
signiﬁcant increase in serum HDL-c compared to control
patients (Fig. 2).
3.2. Results of animal data
After 4 weeks of treatment, doxorubicin-treated or digoxin–
doxorubicin-treated rats appeared more fatigue; had a signiﬁ-
cantly large amount of ascites, had lower SBP compared with
atorvastatin–doxorubicin-treated rats (Table 2) (P< 0.05).
There was an increase in the ﬁnal body weight of atorva-
statin–doxorubicin-treated rats compared to their basal body
weight. However, there was a decrease in the ﬁnal body weight
of the doxorubicin-treated and digoxin–doxorubicin-treated
rats (Table 2). Moreover, heart weight/body weight ratio
(cardiac mass index) was signiﬁcantly increased in
atorvastatin–doxorubicin-treated rats compared to those ofTable 1 Baseline clinical data of all chronic heart failure (CHF) pa
Control gr
Age (years) 59.5 ± 3.5
Sex
Male 14 (70%)
Female 6 (30%)
Risk factors
Hypertension 10 (50%)
Diabetes mellitus 4 (20%)
Smoking 12 (60%)
Family history of CHD 6 (30%)
Concomitant drugs
Digoxin 14 (70%)
Diuretic 18 (90%)
Nitrates 6 (30%)
B-blockers 8 (40%)
ACE inhibitors 16 (80%)
Data are the mean±SD (n= 20). There was no signiﬁcance between the
heart diseases.doxorubicin-treated and digoxin–doxorubicin-treated rats
(P< 0.05) (Table 2).
After 4 weeks of treatment, laboratory assay results in the
doxorubicin-treated rats produced a signiﬁcant (P< 0.05)
increase in the levels of total cholesterol, triglycerides and
LDL-c, but no signiﬁcant increase (P> 0.05) in the HDL-c
levels compared to those of saline-treated rats. Atorvastatin–
doxorubicin-treated rats produced a signiﬁcant decrease in
the level of total cholesterol, triglycerides and LDL-c, and a
signiﬁcant increase in the level of HDL-c compared to doxoru-
bicin-treated rats (P< 0.05). Digoxin–doxorubicin-treated
rats showed no signiﬁcant changes in their lipid proﬁle from
those of doxorubicin-treated rats (P> 0.05) (Fig. 3).
There was a signiﬁcant increase in serum levels of hs-CRP
and cTnT and cardiac tissue MDA in doxorubicin-treated rats
compared with those of saline-treated rats (p< 0.01). The
atorvastatin–doxorubicin treated group produced a signiﬁcant
decrease in the serum levels of hs-CRP and cTnT and cardiac
tissue MDA compared to doxorubicin treated rats (P< 0.01).
Digoxin–doxorubicin treated rats showed no signiﬁcant
changes in their serum levels of hs-CRP and cTnT and cardiac
tissue MDA compared to those of doxorubicin-treated rats
(P> 0.05) (Fig. 3).
3.2.1. Rat histopathology
After 4 weeks of treatment followed by H&E staining, the
myocardial ﬁbers of the saline group were arranged regularly
with clear striations. No apparent degeneration or necrosis
was observed; the cardiac muscle ﬁbers had uniform size and
acidophilic cytoplasm. The nuclei appeared rounded or oval
and centrally located. Doxorubicin-treated rats showed focal
loss in the normal architecture of the cardiac muscle ﬁbers
(myocyte vacuolization and degeneration), with deeply stained
peripheral pyknotic nuclei. Occasionally, some demonstrated
lost nuclei, inﬂammatory cells, and hyalinosis in the wall of
the congested vessels. Atorvastatin–doxorubicin treated rats
displayed overall improvement with a nearly normal appear-
ance of most of the cardiac muscle ﬁbers having centrallytients.
oup Atorvastatin-treated group
60.5 ± 3.9
16 (80%)
4 (20%)
12 (60%)
6 (30%)
14 (70%)
4 (20%)
16 (80%)
16 (80%)
4 (20%)
6 (30%)
18 (90%)
control and atorvastatin treated patients (P> 0.05); CHD, coronary
Figure 1 Echocardiographic data in both patients groups. (a) Left ventricle ejection fraction (LV-EF%), (b) fraction shortening (LV-
FS%), (c) end-diastolic diameter (LV-EDD), (d) end-systolic diameter (LV-ESD) and (e) E/A velocity ratio in control patients (h) and
atorvastatin treated patients (n). Data are given as mean±SD (n= 20). *P< 0.05 compared with control-atorvastatin basal. P< 0.05
compared with control-atorvastatin after 6 weeks.
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showing pyknotic peripheral located nuclei. Digoxin–doxoru-
bicin-treated rats showed less or no improvement in the histo-
logical pictures as seen by the loss of the normal architecture of
the cardiac muscle ﬁbers with degeneration and pyknosis of
the nuclei and extravasation of blood between cardiac muscle
ﬁbers (Fig. 4A–D).
Resorcin-Fuchsin staining for elastic ﬁbers demonstrated
the normal distribution of vessels among cardiac muscle ﬁbers
in the control group. Doxorubicin treated rats showed elastic
ﬁbers in the wall of the congested vessel among the cardiac
muscle ﬁbers. Atorvastatin treated rats showed the appearance
of many vessels in between the cardiac muscle ﬁbers (neo-
angiogenesis) compared to other groups while digoxin treated
rats revealed no change in the blood vessel appearance
(Fig. 4E–H).
Masson’s trichrome staining showed a slight blue color in
the connective tissue in the interstitium and around bloodvessels in the control group. Doxorubicin treated rats showed
marked collagen ﬁbers around the blood vessels and in the
interstitium compared with saline treated rats. Atorvastatin
treated rats showed few collagen ﬁbers in between the cardiac
muscle ﬁbers, and lower ﬁbrotic content than non-treated rats.
Digoxin treated rats showed many collagen ﬁbers around
blood vessels and in the degenerated myocardium (Fig. 4I–L).
4. Discussion
For the ﬁrst time, we have demonstrated that the addition of
atorvastatin to standard heart failure therapy further pre-
vented LV dilatation (decreased LV-ESD and LV-EDD) and
normalized cardiac function (increased LV-EF% and LV-
FS%) compared with standard heart failure therapy in CHF
patients, indicating an additional beneﬁt. Our explanations
of the beneﬁcial effects of atorvastatin were beyond those it
has on plasma lipid levels (decreased total cholesterol,
Table 2 General animal characteristic parameters and tissue weight ratios in different groups of the experimental study.
Saline-treated Doxorubicin-treated Atorvastatin–doxorubicin-treated Digoxin–doxorubicin-treated
Baseline SBP (mmHg) 110.9 ± 1.96 110.2 ± 2.14 110.6 ± 1.89 110.3 ± 2.11
Final SBP (mmHg) 111.5 ± 1.42 82.4 ± 1.82***, 91.25 ± 1.28*,,§, 80.33 ± 1.96**,
Basal body weight (g) 163.2 ± 2.8 162.5 ± 1.26 163.5 ± 1.64 162.6 ± 1.64
Final body weight (g) 210.0 ± 3.26 143.8 ± 2.91***, 172.0 ± 1.98*,,§, 142.0 ± 2.78**,
Heart weight (g) 0.755 ± 0.0193 0.485 ± 0.0078*** 0.602 ± 0.0035*,,§ 0.482 ± 0.0083**
Heart weight/ﬁnal body
weight ratio (g/g)
0.00360 ± 0.00073 0.00337 ± 0.00032*** 0.00350 ± 0.00055*,,§ 0.00336 ± 0.00033**
Volume of ascites (ml) 0 2.75 ± 0.02*** 1.25 ± 0.01*,,§ 2.80 ± 0.03**
Mortality rate % 0 30*** 20*,§ 40**
Data are given as mean±SD (n= 10). Baseline systolic blood pressure (SBP) and body weight were measured immediately prior to drug
administration. The ﬁnal SBP and body weight were measured 4 weeks after drug administration.
* P< 0.01 compared with saline-treated.
** P< 0.01 compared with saline-treated.
*** P< 0.01 compared with saline-treated.
 P< 0.05 compared with doxorubicin-treated.
§ P< 0.05 compared with digoxin-treated.
 P< 0.01 compared with basal parameters in each group.
Figure 2 Laboratory parameters in both CHF patient groups. (a) Serum total cholesterol, (b) serum triglycerides, (c) serum LDL-c, (d)
serumHDL-c, (e) serum cardiac troponin-T (cTnT), (f) serumhs-CRP, and (g) serummalondialdehyde (MDA) aremeasured inCHFpatient
controls (h) and atorvastatin-treated groups (n). Data are given as mean±SD (n= 20). *P< 0.05 compared with control-atorvastatin
basal; P< 0.05 compared with control-atorvastatin after 6 weeks. **P< 0.01 compared with control-atorvastatin after 6 weeks.
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Figure 3 Laboratory parameters in the experimental study. (a) Serum total cholesterol, (b) serum triglycerides, (c) serum LDL-c, (d)
serum HDL-c, (e) serum cardiac troponin-T (cTnT), (f) serum hs-CRP, and (g) cardiac tissue malondialdehyde (MDA) were measured in
all treated rat groups; saline-treated control rats (saline), doxorubicin-treated rats (Dox), atorvastatin–doxorubicin treated rats
(Dox+Ator) and digoxin–doxorubicin treated rats (Dox+Dig). Data are the mean±SD (n= 10). *P< 0.01 compared with saline-
treated rats; **P< 0.01 compared with saline-treated rats; ***P< 0.01 compared with saline-treated rats; P< 0.05 compared with
doxorubicin-treated rats; §P< 0.05 compared with digoxin-treated.
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myocardial remodeling as shown in our doxorubicin
cardiomyopathy rat model by the prevention of cardiac
inﬂammation (decreased serum cTnT, hs-CRP, and MDA),
the reduction of cardiac ﬁbrosis, and associated with neovascu-
larization. Further, clinically, atorvastatin exerted cardiopro-
tective effect (anti-inﬂammatory and anti-oxidant) against
the development of chronic heart failure, whatever the etiol-
ogy, or it can be used routinely for improving cardiomyopathy
in patients with malignant tumors that are being treated by
anthracycline anticancer antibiotics.17,18
4.1. Clinical statin therapy effect
Our clinical echocardiographic data were in agreement with
other clinical results that reported atorvastatin had beneﬁcial
effects for improving heart function (increase in LV-EF%) inCHF patients.13,29 Moreover, many types of statin therapy
improved cardiac function in patients with CHF.13,16,30
Clinically, cTnT and hs-CRP were used as prognostic
markers and indicators of acute coronary syndromes and heart
failure managements.5,31 Our laboratory results showed that
atorvastatin improved cardiac function via exerting potent
anti-inﬂammatory properties. These results were supported
by previous clinical results, that also reported many types of
statins (atorvastatin, lovastatin, pravastatin, ﬂuvastatin,
cerivastatin and simvastatin) reduced the inﬂammatory bio-
markers such as TNF-a, IL1, IL6, IL-10, CRP, cTnT,
BNP,26,30,32–34 and MDA15 in patients with heart failure.
4.2. Animal statin therapy effect
Atorvastatin treatment protected rats against doxorubicin car-
diotoxicity by increasing the body weight, and the heart
Figure 4 Histopathological characteristics of all groups after 4 weeks of treatment. Hematoxylin and Eosin (H&E) staining (A, B, C and
D), Resorcin Fuchsin staining (E, F, G and H), Masson’s trichrome staining (I, J, K and L) in sections of cardiac tissue from saline-treated
control rats (saline) (A, E and I), doxorubicin-treated rats (Dox) (B, F and J), atorvastatin–doxorubicin treated rats (Dox+Ator) (C, G
and K) and digoxin–doxorubicin treated rats (Dox+Dig) (d, h and l). All images are at 400· magniﬁcation (scale bar = 20 lm) except in
the atorvastatin treated group (G1) which was at 200· to show numerous blood vessels (›). A higher magniﬁcation of 1000· (scale
bar = 5 lm) was used in (C1 and C2) to show the congestion of vessels between the cardiac muscle ﬁbers and the centrally located
vesicular nuclei that are in between the cardiac muscle ﬁbers (›) in the atorvastatin treated rats and it was also used in (I1) to show the
elongated vesicular nucleus of the cardiac muscle ﬁbers (›) and the ﬁbroblast in the interstitium (››) in the control group.
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ted or digoxin–doxorubicin-treated rats. These results were
in agreement with others.20
Atorvastatin treatment improved SBP in atorvastatin–
doxorubicin treated rats in comparison to doxorubicin-treated
or digoxin–doxorubicin-treated rats. These results were similar
to other studies on rats with experimental heart failure from
simvastatin and rosuvastatin.9 Statins exert cardiovascular
and renal protection, which is accompanied by blood pressure
reduction; irrespective of serum cholesterol levels.9
Also, in our experimental CHF results were similar to the
clinical results obtained in laboratory serum evaluations.
Additionally, in rats, cTnT may be a useful marker for the
assessment of experimentally doxorubicin-induced
cardiotoxicity.
Our results of atorvastatin–doxorubicin treated rats were in
agreement with others showing a signiﬁcant decrease in serum
cTnT,35 serum hs-CRP9 and cardiac tissue MDA.14,27 The
effect of atorvastatin in reducing MDA could be attributed
to its antioxidant and lipid-lowering properties.
Histology of heart tissues in atorvastatin–doxorubicin
treated rats, showed a reduction in loss of myoﬁbrils,
vacuolization of the cytoplasm and swelling of mitochondria,
coagulative necrosis with focal areas of ﬁbrosis, vascularcongestion, as well as decreased mononuclear cellular inﬁltra-
tion. These results were in agreement with other experimental
results.9,20,36
Atorvastatin increased the formation of new blood vessels
(neo-angiogenesis) between cardiac muscle ﬁbers, but was
absent in both the doxorubicin-treated group and the
digoxin–doxorubicin-treated group. This result previously
reported that statins mobilize endothelial progenitor cells from
the bone marrow that play a role in maintenance of vasculo-
genesis and new blood vessels’ formation.37,38
The use of atorvastatin might be a useful cardio-protective
measure for limiting adverse LV remodeling because of our
demonstration of the decrease of ﬁbrosis and necrosis that
has been similarly observed by other studies.16,19,27 Theses
studied have also shown reduction of hydroxyproline content,
collagen deposition, ﬁbrosis and the apoptosis of cardiomyo-
cytes.16,19,27 Moreover, statin treatment in rats with heart fail-
ure, showed attenuated LV dilatation, improved LV-EF%,
LV-FS% and E/A velocity ratio, and also demonstrated atten-
uated cardiac hypertrophy, ﬁbrosis and inﬂammation when
compared with control rats with heart failure.9,27
Pharmacologically, beyond their lipid-lowering actions,
statins have other potentially favorable ‘‘pleiotropic’’
effects10, including anti-inﬂammatory,13,39 anti-ﬁbrotic,40
Atorvastatin therapy for heart failure 297anti-apoptosis,19 antioxidant effects,14,15 anti-hypertrophic,41
inhibition of neurohormonal activation,29 decrease immune
activation,35 alter metalloproteinase activity,32 and preven-
tion of cardiac arrhythmias42; all of which can contribute
to the improvement of LV function and prevention or
attenuation of progressive LV remodeling in heart failure.
However, for this study, our aim was focused on the anti-
inﬂammatory, anti-ﬁbrotic and antioxidant effects of
atorvastatin.
5. Conclusion
The results of the present clinical and pre-clinical studies sug-
gest that atorvastatin has a beneﬁcial cardio-protective effect
in heart failure. Statins have also been shown to possess a host
of other non-cholesterol lowering properties including the abil-
ity to decrease LV ﬁbrosis and necrosis, decrease inﬂammation
(cTnT and hs-CRP), decrease oxidative stress (MDA), and
induce neo-angiogenesis, all of which can contribute to the
improvement of LV function and prevention or attenuation
of progressive LV remodeling in heart failure. Hence, these
potential cardio-protective pleiotropic actions of atorvastatin
may be of good therapeutic value in management of heart
failure, even in patients for whom the medication may not
otherwise be indicated. Further clinical studies with large num-
ber of patients are now needed in order to clarify whether this
beneﬁcial effect can be translated into clinical practice.Conﬂict of interest
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